P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR
Market Cap: 95.9m EUR
Have any thoughts about
Pierrel SpA?
Write Note

Pierrel SpA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pierrel SpA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
P
Pierrel SpA
MIL:PRL
Cash & Cash Equivalents
€4.8m
CAGR 3-Years
-10%
CAGR 5-Years
33%
CAGR 10-Years
16%
Newron Pharmaceuticals SpA
SIX:NWRN
Cash & Cash Equivalents
€7.9m
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Cash & Cash Equivalents
€200.6m
CAGR 3-Years
-16%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Friulchem SpA
MIL:FCM
Cash & Cash Equivalents
€4.7m
CAGR 3-Years
4%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Cash & Cash Equivalents
€1.2m
CAGR 3-Years
-58%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
No Stocks Found

Pierrel SpA
Glance View

Market Cap
95.9m EUR
Industry
Pharmaceuticals

Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.

PRL Intrinsic Value
1.849 EUR
Undervaluation 6%
Intrinsic Value
Price
P

See Also

What is Pierrel SpA's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.8m EUR

Based on the financial report for Jun 30, 2023, Pierrel SpA's Cash & Cash Equivalents amounts to 4.8m EUR.

What is Pierrel SpA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
16%

Over the last year, the Cash & Cash Equivalents growth was -11%. The average annual Cash & Cash Equivalents growth rates for Pierrel SpA have been -10% over the past three years , 33% over the past five years , and 16% over the past ten years .

Back to Top